Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
about
Arsenic trioxide for the treatment of acute promyelocytic leukaemiaAcute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patientsRisk score model for fatal intracranial hemorrhage in acute leukemia.Thromboembolic and bleeding complications in acute leukemia.Curing all patients with acute promyelocytic leukemia: are we there yet?Treatment advances have not improved the early death rate in acute promyelocytic leukemia.Advances in the understanding and management of acute promyelocytic leukemia.Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centreAcute promyelocytic leukemia: a case-based review.Acute promyelocytic leukaemia:a review.Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.Newly diagnosed acute promyelocytic leukemiaDisparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in CaliforniaEmerging new approaches for the treatment of acute promyelocytic leukemia.Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea.Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia.Bleeding and thrombosis in acute promyelocytic leukemia.Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Treatment of acute promyelocytic leukemia with high white cell blood counts.Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia.Acute promyelocytic leukaemia presenting with subarachnoid haemorrhage and complicated by central nervous system involvement.Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation.High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.A Revised Fibrinogen Cutoff Value in the Chinese Disseminated Intravascular Coagulation Scoring System May Provide a Better Prognostic Value for Hematological Malignancies.The incidence of non-melanoma skin cancer and post-transplant lympho-proliferative disorders in the Scottish cardiac transplant population and the provision of specialist dermatological follow-up.Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early deathInclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL)
P2860
Q24239914-AB5CD0B8-ADB3-4944-9F2C-9E587ACA698CQ28286577-4843463E-5950-42E4-AE78-428432539981Q33370487-19B67264-E3F3-493B-948B-6A0A8E350CFDQ33392897-90E9901F-6EEE-4F48-8EA2-3D620D12C606Q33613426-1FB6F23E-8F1B-42D1-B3AA-0D9C35E327E2Q34223654-506F8706-9F65-4864-9060-139DC420CE28Q34680944-12D255ED-65E2-46BC-8735-E5EF674A1288Q34953881-EF9A75D4-05FE-413B-91D2-D85B651F3BB3Q35127005-D3B29FB6-0B3D-422B-8FED-C0244D7970A0Q35183767-7F7C5285-FCCB-4A9A-8770-849054A76E62Q35186873-7E424234-E128-4D98-ADB1-1520A6037E52Q35640773-963DC706-81A9-4087-87D2-2AA1000D1BF8Q36253767-F44229A7-F83A-4839-93D8-8A6F651B2210Q36612619-557EE7EB-3F06-4C5D-83F1-B3C349FFB168Q36761829-919B6518-4EFE-404F-AB47-51E50C662E2FQ37908158-5AB29D57-8B9C-45D4-8BCA-8B4B255A61E5Q37952402-C2BBB98C-1D0C-4784-BC7E-BB377A84529CQ38006876-198FC958-0920-4E1C-9727-8D852A0F45AAQ38161835-07516DCB-3A54-470E-96DA-2AA69719DF66Q38798789-5D2D097A-36EB-4673-B6C1-E9E0F9E9C5D6Q39021954-46071763-9D49-445E-BA0D-E329D0CB371CQ39023642-F976D517-4C9A-4407-9540-D23FE763FA5FQ40083551-65873C8A-288C-4565-BF83-D8B0D0E957DDQ40297964-EDCE2198-E1DF-43BE-88CE-4EBE654E728EQ42768186-2E6BED5B-404B-4DCC-9801-E3929D9CC4F4Q43278789-F3450DF8-8F2B-4EA9-B53E-968C9D9059F8Q47229461-FB1D7408-15B3-4D0A-A918-59E8175B4F50Q47757780-945361B7-7D6E-4300-A531-988624CAAAECQ48264212-8F201BD3-6D55-4431-B74D-0ED8E180D0BEQ48673716-5531CAD8-4FA1-4F69-A071-09D8B5D04115Q50090795-0AED33DA-0968-410B-B74C-085B025E9AD7Q51474049-DDC9604F-6172-4336-A458-E54D31AC6117Q53194151-492EAF75-1A79-46B6-9B72-46C6553B17F7Q57074270-AF770E8D-A886-4C67-8B84-9E1F0EBAEA82Q57224260-91CDF00F-869D-45B6-95E0-DB01128E6B67
P2860
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@ast
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@en
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@nl
type
label
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@ast
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@en
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@nl
prefLabel
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@ast
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@en
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@nl
P2093
P1476
Early haemorrhagic morbidity a ...... acute promyelocytic leukaemia.
@en
P2093
Avvisati G
Castaman G
De Sanctis V
Luce Vegna M
Mandelli F
Rodeghiero F
P2860
P304
P356
10.1046/J.1365-2141.2000.01936.X
P407
P577
2000-03-01T00:00:00Z